Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm

Vaccine

Volumn 33, Issue 39, 2015, Pages 5172-5180

  Rudd, Penny A ^a,c   Raphael, Anthony P ^b   Yamada, Miko ^b   Nufer, Kaitlin L ^b   Gardner, Joy ^a   Le, Thuy T T ^a   Prow, Natalie A ^a,b   Dang, Nhung ^b   Schroder, Wayne A ^a   Prow, Tarl W ^b   Suhrbier, Andreas ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

Chikungunya virus; Cutaneous vaccination; Foroderm; Vaccine delivery

Indexed keywords

INACTIVATED CHIKUNGUNYA VIRUS VACCINE; INACTIVATED VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; INACTIVATED VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG DELIVERY SYSTEM; EPIDERMIS; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; VACCINATION; VIREMIA; ANIMAL; BLOOD; CHIKUNGUNYA FEVER; DISEASE MODEL; IMMUNOLOGY; INBRED MOUSE STRAIN; INTRADERMAL DRUG ADMINISTRATION; NUDE MOUSE; T LYMPHOCYTE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, VIRAL; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; MICE, INBRED STRAINS; MICE, NUDE; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, INACTIVATED; VIRAL VACCINES; VIREMIA;

EID: 84941662138     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.099     Document Type: Article

References (39)

1. Matsuo K., Hirobe S., Okada N., Nakagawa S. Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery. Vaccine 2013, 31:2403-2415.
2. Gill H.S., Kang S.M., Quan F.S., Compans R.W. Cutaneous immunization: an evolving paradigm in influenza vaccines. Expert Opin Drug Deliv 2014, 11:615-627.
3. Jain A., Jain P., Kurmi J., Jain D., Jain R., Chandel S., et al. Novel strategies for effective transdermal drug delivery: a review. Crit Rev Ther Drug Carrier Syst 2014, 31:219-272.
4. Kim Y.C., Park J.H., Prausnitz M.R. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012, 64:1547-1568.
5. Prow T.W., Chen X., Prow N.A., Fernando G.J., Tan C.S., Raphael A.P., et al. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 2010, 6:1776-1784.
6. Depelsenaire A.C., Meliga S.C., McNeilly C.L., Pearson F.E., Coffey J.W., Haigh O.L., et al. Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity. J Invest Dermatol 2014, 134:2361-2370.
7. Al-Zahrani S., Zaric M., McCrudden C., Scott C., Kissenpfennig A., Donnelly R.F. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy. Expert Opin Drug Deliv 2012, 9:541-550.
8. Raphael A.P., Primiero C.A., Ansaldo A.B., Keates H.L., Soyer H.P., Prow T.W. Elongate microparticles for enhanced drug delivery to ex vivo and in vivo pig skin. J Control Release 2013, 172:96-104.
9. Raphael A.P., Primiero C.A., Lin L.L., Smith R.F., Dyer P., Soyer H.P., et al. High aspect ratio elongated microparticles for enhanced topical drug delivery in human volunteers. Adv Healthc Mater 2014, 3:860-866.
10. Suhrbier A., Jaffar-Bandjee M.C., Gasque P. Arthritogenic alphaviruses-an overview. Nat Rev Rheumatol 2012, 8:420-429.
11. Weaver S.C. Arrival of chikungunya virus in the new world: prospects for spread and impact on public health. PLoS Negl Trop Dis 2014, 8:e2921.
12. Horwood P., Bande G., Dagina R., Guillaumot L., Aaskov J., Pavlin B. The threat of chikungunya in Oceania. West Pac Surveill Response J 2013, 4:8-10.
13. Enserink M. Infectious diseases. Crippling virus set to conquer Western Hemisphere. Science 2014, 344:678-679.
14. Edelman R., Tacket C.O., Wasserman S.S., Bodison S.A., Perry J.G., Mangiafico J.A. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000, 62:681-685.
15. Chang L.J., Dowd K.A., Mendoza F.H., Saunders J.G., Sitar S., Plummer S.H., et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014, 384:2046-2052.
16. Metz S.W., Gardner J., Geertsema C., Le T.T., Goh L., Vlak J.M., et al. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 2013, 7:e2124.
17. Garcia-Arriaza J., Cepeda V., Hallengard D., Sorzano C.O., Kummerer B.M., Liljestrom P., et al. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol 2014, 88:3527-3547.
18. Wang D., Suhrbier A., Penn-Nicholson A., Woraratanadharm J., Gardner J., Luo M., et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 2011, 29:2803-2809.
19. Gardner J., Anraku I., Le T.T., Larcher T., Major L., Roques P., et al. Chikungunya virus arthritis in adult wild-type mice. J Virol 2010, 84:8021-8032.
20. Wressnigg N., van der Velden M.V., Portsmouth D., Draxler W., O'Rourke M., Richmond P., et al. An inactivated Ross river virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial. Clin Vaccine Immunol 2015, 22:267-273.
21. Poo Y.S., Rudd P.A., Gardner J., Wilson J.A., Larcher T., Colle M.A., et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl Trop Dis 2014, 8:e3354.
22. Selvarajah S., Sexton N.R., Kahle K.M., Fong R.H., Mattia K.A., Gardner J., et al. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis 2013, 7:e2423.
23. Goh L.Y., Hobson-Peters J., Prow N.A., Gardner J., Bielefeldt-Ohmann H., Pyke A.T., et al. Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. Clin Immunol 2013, 149:487-497.
24. Holzer G.W., Coulibaly S., Aichinger G., Savidis-Dacho H., Mayrhofer J., Brunner S., et al. Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine 2011, 29:4132-4141.
25. Sergon K., Yahaya A.A., Brown J., Bedja S.A., Mlindasse M., Agata N., et al. Seroprevalence of chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg 2007, 76:1189-1193.
26. Josseran L., Paquet C., Zehgnoun A., Caillere N., Le Tertre A., Solet J.L., et al. Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 2006, 12:1994-1995.
27. Frank C., Mohamed M.K., Strickland G.T., Lavanchy D., Arthur R.R., Magder L.S., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355:887-891.
28. Cozzi S.J., Ogbourne S.M., James C., Rebel H.G., de Gruijl F.R., Ferguson B., et al. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol 2012, 132:1263-1271.
29. Rudd P.A., Wilson J., Gardner J., Larcher T., Babarit C., Le T.T., et al. Interferon response factors 3 and 7 protect against chikungunya virus hemorrhagic fever and shock. J Virol 2012, 86:9888-9898.
30. Martin R.M., Brady J.L., Lew A.M. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 1998, 212:187-192.
31. Lefeber D.J., Benaissa-Trouw B., Vliegenthart J.F., Kamerling J.P., Jansen W.T., Kraaijeveld K., et al. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect Immun 2003, 71:6915-6920.
32. La Linn M., Gardner J., Warrilow D., Darnell G.A., McMahon C.R., Field I., et al. Arbovirus of marine mammals: a new alphavirus isolated from the elephant seal louse, Lepidophthirus macrorhini. J Virol 2001, 75:4103-4109.
33. Koutsonanos D.G., Compans R.W., Skountzou I. Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol 2013, 785:121-132.
34. Robertson K., Rees J.L. Variation in epidermal morphology in human skin at different body sites as measured by reflectance confocal microscopy. Acta Derm Venereol 2010, 90:368-373.
35. Khawaja R.A., Sikandar R., Qureshi R., Jareno R.J.M. Routine skin preparation with 70% isopropyl alcohol swab: is it necessary before an injection? Quasi study. JLUMHS 2013, 12:109-114.
36. O'Neill J., Grinager H., Smith S.D., Sibley S., Harrison A.R., Lee M.S. Isopropyl alcohol skin antisepsis does not reduce incidence of infection following insulin injection. Am J Infect Control 2013, 41:755-756.
37. Kuroda E., Coban C., Ishii K.J. Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol 2013, 32:209-220.
38. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., et al. Pathogen recognition and development of particulate vaccines: does size matter. Methods 2006, 40:1-9.
39. Hirobe S., Azukizawa H., Matsuo K., Zhai Y., Quan Y.S., Kamiyama F., et al. Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm Res 2013, 30:2664-2674.